MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology...

Related Keywords

Ireland ,Switzerland ,Dublin ,Germany ,Berlin ,Hidradenitis Suppurativa ,Ashley Tapp ,Kristian Reich ,Mary Jane Elliott ,Moonlake Immunotherapeutics ,Matthias Bodenstedt ,Patricia Sousa ,Namrata Taak ,American College Of Rheumatology Conference ,Charles Institute Of Dermatology ,International Hidradenitis Suppurativa Severity Score System ,Vincent University Hospital ,Exchange Commission ,European Academy Of Dermatology ,Venereology Congress ,University College Dublin ,Charles Department Of Dermatology ,Nasdaq ,European Academy ,Professor Brian Kirby ,Charles Department ,University Hospital ,Charles Institute ,Chief Scientific Officer ,American College ,Rheumatology Conference ,Hidradenitis Suppurativa Clinical Response ,Dermatology Life Quality Index ,Numerical Rating Scale ,Global Assessment ,Skin Pain ,Global Assessment Score ,Psoriasis Area ,Severity Index ,Securities Litigation Reform Act ,Annual Report ,Jane Elliott ,Markets ,